| Report ID | 275306 |
| Drug Identification Number | 02241472 |
| Brand name | TAMIFLU |
| Common or Proper name | Oseltamivir |
| Company Name | HOFFMANN-LA ROCHE LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | OSELTAMIVIR |
| Strength(s) | 75MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | Blister pack of 10 |
| ATC code | J05AH |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2026-03-30 |
| Actual start date | |
| Estimated end date | 2026-05-01 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2026-01-06 |
| Company comments | Anticipated shortage due to usage of 75mg for compounding purposes with the recent market shortages of Tamiflu Powder for Oral Suspension. The order quantities will be monitored and allocated on an as needed basis to ensure equitable distribution. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 7070 MISSISSAUGA ROAD MISSISSAUGA, ONTARIO CANADA L5N 5M8 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2026-01-06 | French | Compare |
| v1 | 2026-01-06 | English | Compare |
Showing 1 to 2 of 2